{"nctId":"NCT01960348","briefTitle":"APOLLO: The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis","startDateStruct":{"date":"2013-11"},"conditions":["TTR-mediated Amyloidosis","Amyloidosis, Hereditary","Amyloid Neuropathies, Familial","Familial Amyloid Polyneuropathies","Amyloid Neuropathies","Amyloidosis, Hereditary, Transthyretin-Related"],"count":225,"armGroups":[{"label":"patisiran (ALN-TTR02)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: patisiran (ALN-TTR02)"]},{"label":"Sterile Normal Saline (0.9% NaCl)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Sterile Normal Saline (0.9% NaCl)"]}],"interventions":[{"name":"patisiran (ALN-TTR02)","otherNames":[]},{"name":"Sterile Normal Saline (0.9% NaCl)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female of 18 to 85 years of age (inclusive);\n* Have a diagnosis of FAP\n* Neuropathy Impairment Score requirement of 5-130\n* Meet Karnofsky performance status requirements\n* Have adequate complete blood counts and liver function tests\n* Have adequate cardiac function\n* Have negative serology for hepatitis B virus (HBV) and hepatitis C virus (HCV)\n\nExclusion Criteria:\n\n* Had a prior liver transplant or is planned to undergo liver transplant during the study period;\n* Has untreated hypo- or hyperthyroidism;\n* Has known human immunodeficiency virus (HIV) infection;\n* Had a malignancy within 2 years, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated;\n* Recently received an investigational agent or device\n* Is currently taking diflunisal, tafamidis, doxycycline, or tauroursodeoxycholic acid","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Modified Neuropathy Impairment Score +7 (mNIS+7)","description":"The difference between the patisiran (ALN-TTR02) and placebo groups in the change from baseline in mNIS+7 at 18 months. The mNIS+7 is a composite score that quantitates motor, sensory, and autonomic neurologic impairment due to injury of large and small nerves. The minimum and maximum values are 0 and 304, respectively. A higher score indicates a worse outcome.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.03","spread":"1.739"},{"groupId":"OG001","value":"27.96","spread":"2.602"}]}]}]},{"type":"SECONDARY","title":"Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QoL-DN) Questionnaire","description":"The difference between the patisiran (ALN-TTR02) and placebo groups in the change from baseline in Norfolk QoL-DN at 18 months. The Norfolk QoL-DN questionnaire is a standardized 35-item patient-reported outcomes measure that is sensitive to the different features of diabetic neuropathy - small fiber, large fiber, and autonomic nerve function. The minimum and maximum values are -4 and 136, respectively. A higher score indicates a worse outcome.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.7","spread":"1.77"},{"groupId":"OG001","value":"14.4","spread":"2.73"}]}]}]},{"type":"SECONDARY","title":"Neurological Impairment Score-Weakness (NIS-W) Score","description":"The difference between the patisiran (ALN-TTR02) and placebo groups in the change from baseline in NIS-W at 18 months. NIS-W is a measure of motor strength, comprised of cranial nerve and both upper and lower limb motor assessments. The minimum and maximum values are 0 and 192, respectively. A higher score indicates a worse outcome.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"1.306"},{"groupId":"OG001","value":"17.93","spread":"1.959"}]}]}]},{"type":"SECONDARY","title":"Rasch-built Overall Disability Scale (R-ODS) Score","description":"The difference between the patisiran (ALN-TTR02) and placebo groups in the change from baseline in R-ODS score at 18 months. The R-ODS is comprised of a 24-item linearly weighted scale that specifically captures activity and social participation limitations in patients. The minimum and maximum values are 0 and 48, respectively. A higher score indicates a better outcome.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"0.59"},{"groupId":"OG001","value":"-8.9","spread":"0.88"}]}]}]},{"type":"SECONDARY","title":"Timed 10-meter Walk Test (10-MWT, Gait Speed)","description":"The difference between the patisiran (ALN-TTR02) and placebo groups in the change from baseline in 10-MWT at 18 months. Ability to ambulate (gait speed) was assessed through the 10-meter walk test (10-MWT). The walk had to be completed without assistance from another person; ambulatory aids such as canes and walkers were permitted.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.077","spread":"0.0242"},{"groupId":"OG001","value":"-0.235","spread":"0.0358"}]}]}]},{"type":"SECONDARY","title":"Modified Body Mass Index (mBMI)","description":"The difference between the patisiran (ALN-TTR02) and placebo groups in the change from baseline in mBMI at 18 months. The nutritional status of patients was evaluated using the mBMI; calculated as the product of BMI (weight in kilograms divided by the square of height in meters) and serum albumin (g/L).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.7","spread":"9.57"},{"groupId":"OG001","value":"-119.4","spread":"14.51"}]}]}]},{"type":"SECONDARY","title":"Autonomic Symptoms Questionnaire (Composite Autonomic Symptom Score [COMPASS 31])","description":"The difference between the patisiran (ALN-TTR02) and placebo groups in the change from baseline in COMPASS 31 at 18 months. The COMPASS 31 is a measure of autonomic neuropathy symptoms. The questions evaluated 6 autonomic domains (orthostatic intolerance, vasomotor, secretomotor, gastrointestinal, bladder, and pupillomotor). The minimum and maximum values are 0 and 100, respectively. A higher score indicates a worse outcome.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.29","spread":"1.300"},{"groupId":"OG001","value":"2.24","spread":"1.940"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":54,"n":148},"commonTop":["Diarrhoea","Oedema peripheral","Fall","Nausea","Infusion related reaction"]}}}